Pharmacoeconomic Aspects of Treating Childhood Pneumonia - Cost of Illness Study Based on Data from Serbia-Reference-Cited by-同舟云学术

Pharmacoeconomic Aspects of Treating Childhood Pneumonia - Cost of Illness Study Based on Data from Serbia

Published:2024-03-01 Issue:1 Volume:25 Page:57-62
ISSN:2956-2090
Container-title:Experimental and Applied Biomedical Research (EABR)
language:en
Short-container-title:

Author:

Kostić Marina J.¹,Vučković Živan M.²,Desnica Jana V.³,Knežević Sanja M.⁴,Knežević Jasmina⁴,Janković Slobodan M.¹

Affiliation:

1. University of Kragujevac, Faculty of Medical Sciences , Department of Pharmacology and Toxicology , Kragujevac , Serbia

2. University of Kragujevac, Serbia, Faculty of Medical Sciences , Department of Pharmacy , Kragujevac , Serbia

3. University of Kragujevac, Serbia, Faculty of Medical Sciences , Department of Dentistry , Kragujevac , Serbia

4. University of Kragujevac, Serbia, Faculty of Medical Sciences , Department of Pediatrics , Kragujevac , Serbia

Abstract

Abstract The pharmacoeconomic aspect of the treatment of pneumonia in the pediatric population is scarce analyzed in the countries of the Balkan region. This research aimed to determine the value of total hospital costs of treating childhood pneumonia from the Republic Fund of Health Insurance perspective. This retrospective cost of illness study was performed using the “from the bottom to the top” approach. It included 82 patients with childhood pneumonia who were treated at Clinical for pediatrics at Clinical Centre Kragujevac. The total costs of hospital treatment of pneumonia for the examined population were 4,095,293.73 RSD. The largest share in total hospital costs has the length of patient hospitalization (22%). The median total hospital costs per patient per year amounted to 40,249.91 RSD (4,793.10 - 142,149.63 RSD). Since the main determinants of overall costs of treating childhood pneumonia are the length of stay and noninvasive ventilation rate, therapeutic strategies should provide not only efficient treatment in compliance with current guidelines as also decreasing these determinants to offer a better pharmacoeconomic profile of childhood pneumonia.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/sjecr-2021-0040

Reference24 articles.

1. Goodman D, Crocker ME, Pervaiz F, McCollum ED, Steenland K, Simkovich SM, Miele CH, Hammitt LL, Herrera P, Zar HJ, Campbell H, Lanata CF, McCracken JP, Thompson LM, Rosa G, Kirby MA, Garg S, Thangavel G, Thanasekaraan V, Balakrishnan K, King C, Clasen T, Checkley W; HAPIN Investigators. Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group. Lancet Respir Med. 2019;7(12):1068-1083.

2. Elemraid MA, Muller M, Spencer DA, Rushton SP, Gorton R, Thomas MF, et al. Accuracy of the interpretation of chest radiographs for the diagnosis of paediatric pneumonia. PLoS One. 2014;9(8):e106051.

3. Sulley S, Ndanga M. Pediatric pneumonia: An analysis of cost & outcome influencers in the United States. Int J Pediatr Adolesc Med. 2019;6(3):79-86.

4. Gereige RS, Laufer PM. Pneumonia. Pediatr Rev. 2013;34(10):438-56.

5. Zhang S, Sammon PM, King I, Andrade AL, Toscano CM, Araujo SN, Sinha A, Madhi SA, Khandaker G, Yin JK, Booy R, Huda TM, Rahman QS, El Arifeen S, Gentile A, Giglio N, Bhuiyan MU, Sturm-Ramirez K, Gessner BD, Nadjib M, Carosone-Link PJ, Simões EA, Child JA, Ahmed I, Bhutta ZA, Soofi SB, Khan RJ, Campbell H, Nair H. Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health. 2016;6(1):010408.